MGC PHARMACEUTICALS LIMITED (MXC)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
MXC - MGC PHARMACEUTICALS LIMITED
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.51
Index:
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.006
02 Jun |
0.000 OPEN $0.01 |
0.000 HIGH $0.01 |
186,863 LOW $0.01 |
| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BNO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . KZA . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TLX . TRP . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -0.8 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 4.7 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 0.2 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -12.2 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -430.00 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -206.87 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -173.76 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -95.10 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -206.87 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -87.85 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -14.9 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 4 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 2 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 7.48 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 2.7 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 56.91 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 3 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 14 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 3 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
MXC STOCK CHART
FNArena News on MXC
| 1 |
Australian Broker Call *Extra* Edition – Jan 17, 2022Jan 17 2022 - Daily Market Reports |
| 2 |
Risks Of Investing In Medical CannabisJun 07 2017 - FYI |
| 3 |
Investor Optimism Keeps The Bull AliveMar 29 2017 - Rudi's View |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Dr Boreham’s Crucible: Chimeric TherapeuticsMay 26 2023 - Small Caps |
| 2 |
Avita Medical Preps For Enlarged US OpportunityMay 17 2023 - Small Caps |
| 3 |
Dr Boreham’s Crucible: Radiopharm TheronosticsApr 13 2023 - Small Caps |
| 4 |
Dr Boreham’s Crucible: Avita MedicalMar 29 2023 - Small Caps |
| 5 |
Telix Pharmaceuticals’ Pipeline Full Of PromiseMar 21 2023 - Small Caps |
| 6 |
FDA Approval Puts Rocket Under Neuren SharesMar 16 2023 - Small Caps |
| 7 |
Dr Boreham’s Crucible: Actinogen MedicalNov 30 2022 - Small Caps |
| 8 |
Dr Boreham’s Crucible: Qbiotics GroupNov 09 2022 - Small Caps |
| 9 |
Dr Boreham’s Crucible: PharmaxisOct 05 2022 - Small Caps |
| 10 |
Brokers Review Prospects For CSLSep 30 2022 - Australia |
